ALTASCIENCES
17.3.2021 14:59:08 CET | Business Wire | Press release
Altasciences , working with the National Research Council of Canada (NRC), has qualified a quantitative serological assay for the detection of SARS-CoV-2 IgG antibodies, to support vaccine development in studies from discovery to Phase II.
The development of this assay represents an important endpoint in vaccine development, serving to ensure an antibody immune response is generated against the vaccine, and the response ultimately correlates with neutralization of the COVID-19 virus.
Dr. Lynne Le Sauteur, Vice President, Laboratory Sciences, shares what makes this assay qualification unique: “This assay is different from other developments in that it is quantitative, giving an indication of the magnitude of the antibody response, whereas other assays typically provide qualitative yes/no results. The assay was qualified in a GLP laboratory, using a source of spike protein that is reliably and robustly produced in Canada. We are proud of the success of this qualification, which could not have been achieved without seamless teamwork, scientific expertise in vaccine assay development, and the source of study subject patient serum from Altasciences’ clinics (both with and without SARS-CoV-2 infection) that were needed to qualify the assay. It was a truly collaborative achievement.”
Altasciences has over 260 laboratory sciences experts specialized in bioanalysis, ligand binding assays, mass spectrometry, immunology, biomarkers, and molecular biology generating the quality data needed for successful preclinical to clinical drug and vaccine development.
Altasciences worked with the NRC to test various antigens and select the best reagents for the assay. In addition, the NRC produced and characterized the spike protein of the SARS-CoV-2 virus that was used in the testing.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005588/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Opensignal Crowns the World's Best 5G Networks29.9.2026 10:18:00 CEST | Press release
Annual Global 5G Awards Name Worldwide Winners, Leaders, And Rising Stars from Billions of Real-World User Experiences Opensignal, a global independent consumer connectivity analytics and insights company, today announced its annual Opensignal 5G Global Mobile Network Experience Awards, recognizing the providers delivering the best real-world 5G experiences across their national mobile networks. The awards assess billions of real-world user experiences across Download Speed, Video, Games, Voice App, Reliability, Coverage Experience, and — new for 2026 — Time on 5G, collected between Jan. 1 and June 29, 2026. "The consumer connectivity experience is at the core of everything we do at Opensignal. As the role of 5G in modern life grows, the bar for what great 5G looks like keeps rising," said Shawn Heidel, President, Network Experience at Opensignal. "The best operators in the world are defined by how well they deliver on that challenge, and this year's Global 5G Award winners set the sta
ClickHouse Expands Collaboration With Microsoft, Bringing Fabric Integration, Deeper OneLake Interoperability, and Enterprise Deployment Flexibility29.9.2026 09:30:00 CEST | Press release
ClickHouse, the company behind the open-source, real-time analytical database that has become the data layer for the AI era, today at The European Microsoft Fabric + SQL Community Conference announced a significant expansion of its strategic collaboration with Microsoft. The announcement encompasses four major milestones: the launch of the native ClickHouse workload for Microsoft Fabric, the general availability of OneLake read, the public preview of OneLake write, and the availability of ClickHouse Bring Your Own Cloud (BYOC) in the Microsoft Marketplace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929947201/en/ ClickHouse expands collaboration with Microsoft This expansion builds on ClickHouse's growing presence within the Microsoft ecosystem, where data-intensive organizations rely on ClickHouse Cloud on Azure to power real-time observability, business intelligence, AI/ML pipelines, and analytical applications at sc
Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro29.9.2026 09:01:00 CEST | Press release
Opengear’s network resilience solutions now available across 20 European markets Opengear, a Digi International company (NASDAQ: DGII) and global leader in out-of-band management solutions, has signed its first pan-European distribution agreement with Ingram Micro, one of the world’s largest technology distributors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929668925/en/ Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro The agreement will give resellers in participating Ingram Micro countries access to Opengear’s portfolio, supported by Ingram Micro's regional infrastructure, logistics capabilities and partner network. This expands Opengear’s existing reach in the UK, Ireland, Spain, Germany, Italy, France, Belgium and Luxembourg, and brings its network resilience platform to resellers and end-users in additional European markets, such as Switzerland, Hungary, and Czech Republic. “T
Freemarket and Axiym launch LIQUI-DT™ – real-time business access to primary-market USD₮ from Tether29.9.2026 08:00:00 CEST | Press release
Freemarket and Axiym today launched a world-first service that gives businesses 24/7 real-time access to freshly minted, primary-market USD₮ issued by Tether. LIQUI-DTTM gives businesses compliant access to primary market stablecoins inside a fully regulated payment ecosystem via Freemarket’s global payment network. In audited trials, clients have minted or burned more than $300 million to date. Institutional users and high-volume traders will benefit from superior price certainty and direct liquidity giving them budgetary control. As the USD₮ is minted directly in the primary market, treasury and compliance teams have clear provenance for internal reporting 1. The LIQUI-DT service works because while no single party owns the whole stack, it is integrated into the Freemarket network. The combination of Freemarket’s compliant fiat rails and payment network, Axiym’s liquidity engine and on-chain settlement layer and Tether’s primary market issuance creates a regulated payments network wi
Estonia and Owkin Partner to Advance Sovereign AI in Biology29.9.2026 08:00:00 CEST | Press release
Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metrosert, Estonia’s state-owned applied research organisation. The collaboration will evaluate how K Pro, Owkin’s AI scientist platform, can help approved researchers work with complex Estonian health data inside secure national infrastructure, enabling reproducible analysis, and faster generation of scientific insight while preserving data sovereignty. The first phase will focus on selected Estonian health-data cohorts, with Owkin and Metrosert also exploring high-value research areas including oncology, where linked clinical, molecular, imaging and treatment-outcome data could support future biomedical research. Estonia has built one of the world’s most advanced digital public infrastructures and holds population-scale health and biomedical data assets. The partnership will explore how these foundations can
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom